Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Portfolio Pulse from
Akeso Inc. reported significant progress in 2024, including approvals for cadonilimab and ivonescimab in multiple cancer indications, successful inclusion in the National Reimbursement Drug List (NRDL), and expansion of its global clinical trials. The company achieved RMB 2 billion in new drug sales, representing a 25% year-on-year increase, and continues to advance its oncology and non-oncology pipelines.
March 30, 2025 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The company achieved significant commercial and clinical milestones, including drug approvals, NRDL inclusion, and expansion of clinical trials across multiple cancer indications.
Strong clinical progress, successful drug approvals, NRDL inclusion, and expansion of global clinical trials indicate positive momentum for the company's stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100